The authors found cumulative direct costs among patients with metastatic HER2-positive breast cancer to be $412,903 (~ EUR 302,000) during the three years after diagnosis, primarily driven by outpatient visits and HER2-targeted therapy drug costs. This evidence concerns the gene ERBB2 and breast cancer.